Geode Capital Management
PMCB icon

Geode Capital Management’s PharmaCyte Biotech PMCB Stock Holding History

Geode Capital Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.7K Sell
124,247
-71,413
-36% -$53.8K ﹤0.01% 4108
2026
Q1 		$130K Buy
195,660
+71,816
+58% +$54.9K ﹤0.01% 4063
2025
Q4 		$89.7K Sell
123,844
-2,759
-2% -$2.48K ﹤0.01% 4123
2025
Q3 		$123K Hold
126,603
– – ﹤0.01% 4075
2025
Q2 		$139K Sell
126,603
-12,332
-9% -$13.8K ﹤0.01% 3978
2025
Q1 		$174K Sell
138,935
-25,801
-16% -$41.9K ﹤0.01% 3889
2024
Q4 		$255K Sell
164,736
-3,464
-2% -$5.98K ﹤0.01% 3817
2024
Q3 		$321K Sell
168,200
-8,405
-5% -$15.7K ﹤0.01% 3742
2024
Q2 		$346K Sell
176,605
-23,676
-12% -$51K ﹤0.01% 3710
2024
Q1 		$475K Sell
200,281
-15,356
-7% -$33.2K ﹤0.01% 3638
2023
Q4 		$466K Sell
215,637
-3,473
-2% -$7.53K ﹤0.01% 3642
2023
Q3 		$460K Buy
219,110
+36
+0% +$92 ﹤0.01% 3630
2023
Q2 		$627K Buy
219,074
+43,810
+25% +$131K ﹤0.01% 3557
2023
Q1 		$510K Hold
175,264
– – ﹤0.01% 3641
2022
Q4 		$511K Sell
175,264
-343
-0.2% -$982 ﹤0.01% 3650
2022
Q3 		$421K Hold
175,607
– – ﹤0.01% 3811
2022
Q2 		$396K Buy
175,607
+4,084
+2% +$8.93K ﹤0.01% 3891
2022
Q1 		$394K Buy
171,523
+87,948
+105% +$195K ﹤0.01% 4062
2021
Q4 		$208K Buy
83,575
+36,965
+79% +$102K ﹤0.01% 4457
2021
Q3 		$147K Buy
+46,610
New +$164K ﹤0.01% 4557

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Geode Capital Management's PMCB Position: Q2 2026 in Review

Geode Capital Management reduced its PharmaCyte Biotech (PMCB) stake by 36% in Q2 2026, selling an estimated $53.8K and leaving 124,247 shares worth $95.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4108.

Geode Capital Management first reported a position in PMCB in Q3 2021 and has held it in 20 quarters since. The position peaked at $627K in Q2 2023. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Geode Capital Management held 124,247 shares of PharmaCyte Biotech worth $95.7K as of Q2 2026.
  • Geode Capital Management sold 71,413 PharmaCyte Biotech shares in Q2 2026, an estimated $53.8K.
  • PharmaCyte Biotech made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4108 holding.
  • Geode Capital Management first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 20 quarters since.
  • Geode Capital Management's PharmaCyte Biotech position peaked at $627K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.